Salmedix
San Diego
About Salmedix
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $72.5M
- Funding stage: M&A
- Last round: Series C (Oct 2005)
- Website: salmedix.com
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/salmedix-2114274 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.